The DJS Law Group reiterated a securities class action against ADMA Biologics (NASDAQ: ADMA), alleging violations of §§10(b) and 20(a) and Rule 10b-5. The article provides no new financial figures, but the legal overhang can keep investor sentiment cautious toward the stock.
The DJS Law Group reiterated a securities class action against ADMA Biologics (NASDAQ: ADMA), alleging violations of §§10(b) and 20(a) and Rule 10b-5. The article provides no new financial figures, but the legal overhang can keep investor sentiment cautious toward the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
